The study will compare the clinical efficacy of BMS-188667 versus placebo in children and adolescents with JRA/JIA in whom a response had been initially induced by 4 months of open-label therapy. Following 6 months of double-blind treatment, clinical efficacy will be measured by the time to occurrence of JRA/JIA disease flare during the double-blind treatment period.